Midazolam Dosing by Age Group
Midazolam dosing is weight-based (mg/kg) rather than strictly age-based, with younger pediatric patients requiring higher per-kilogram doses than adults, and elderly patients requiring significant dose reductions due to altered pharmacokinetics.
Pediatric Dosing (Non-Neonatal)
Infants and Young Children (6 months to 5 years)
Intravenous:
- Initial dose: 0.05-0.10 mg/kg administered over 2-3 minutes 1, 2
- Total dose may reach 0.6 mg/kg to achieve desired sedation (usually not exceeding 6 mg) 1, 2
- Children <6 years may require up to 1 mg/kg orally 1
- Critical caveat: Higher doses are associated with prolonged sedation and increased risk of hypoventilation 1
Oral:
Intramuscular:
- 0.1-0.15 mg/kg for sedation/anxiolysis 1
- Doses up to 0.5 mg/kg have been used for more anxious patients (total usually not exceeding 10 mg) 2
For RSI (Rapid Sequence Intubation):
School-Age Children (6 to 12 years)
Intravenous:
- Initial dose: 0.025-0.05 mg/kg 1, 2
- Total dose up to 0.4 mg/kg may be needed (usually not exceeding 10 mg) 1, 2
- Higher doses associated with prolonged sedation and hypoventilation risk 1
Adolescents (12 to 16 years)
- Dose as adults 1, 2
- Total dose usually does not exceed 10 mg 1
- Some patients may require higher than recommended adult doses 2
Neonates (<6 months)
Critical population with unique considerations:
- Limited data available for non-intubated neonates <6 months 2
- Particularly vulnerable to airway obstruction and hypoventilation 2
- Titrate with small increments to clinical effect with careful monitoring 2
- Initial dose: 0.05-0.1 mg/kg IV if used 2
- Prolonged elimination half-life (6.5-12.0 hours) in seriously ill neonates compared to 0.78-3.3 hours in older children 2
- Reduced clearance (0.07-0.12 L/hr/kg) versus older pediatric patients 2
Adult Dosing
Healthy Adults (<60 years)
Intravenous for Sedation:
- Initial dose: 1-2 mg (or no more than 0.03 mg/kg) over 1-2 minutes 3, 4, 3
- Additional doses: 1 mg (or 0.2-0.3 mg/kg) at 2-minute intervals until adequate sedation 3
- Total dose usually ≤6 mg for routine procedures 3, 4, 3
- Peak effect: 3-4 minutes after IV administration 3, 4
Important timing consideration: Wait 2-3 minutes between doses to fully evaluate sedative effect before repeating 2
Elderly (≥60 years)
Require significant dose reduction due to pharmacokinetic changes:
- Reduce initial dose by 20% or more 3, 4, 3
- Plasma half-life approximately doubled compared to younger adults 2
- Volume of distribution increased 15-100% 2
- Clearance decreased approximately 25% 2
- When combined with opioids, reduce dose by 50% or more 3
Special Adult Populations
Obese Patients:
- Calculate dose based on ideal body weight, not total body weight 2
- Mean half-life increased (5.9 vs 2.3 hours in normal weight) 2
Hepatic Impairment:
- Reduce dose significantly 2
- Half-life increased 2.5-fold in alcoholic cirrhosis 2
- Clearance reduced by 50% 2
Renal Failure:
- Clearance reduced (1.9 vs 2.8 mL/min/kg) 2
- Half-life prolonged (7.6 vs 13 hours) 2
- Expect slower recovery 2
Congestive Heart Failure:
- Two-fold increase in elimination half-life 2
- 25% decrease in clearance 2
- 40% increase in volume of distribution 2
Critical Safety Considerations
Respiratory Depression Risk:
- Synergistic effect when combined with opioids - reduce midazolam dose accordingly 3, 4, 3
- Apnea may occur up to 30 minutes after last dose 4
- More rapid administration results in greater respiratory depression 4
- Always have flumazenil available, though it reverses anticonvulsant effects and may precipitate seizures 1
Monitoring Requirements:
- Continuous oxygen saturation monitoring 1
- Be prepared to provide respiratory support 1, 2
- Observe for paradoxical agitation, especially in younger children 1
Dose Titration Principle: